The roles and mechanisms of coding and noncoding RNA variations in cancer

참고문헌 (176)

1. Yang, H. D., "Pathogenic diversity of RNA variants and RNA variation-associated factors in cancer development", Exp. Mol. Med, 52, pp.582~593 (2020)
2. Delaunay, S., "RNA modifications in physiology and disease : towards clinical applications", Nat. Rev. Genet, 25, pp.104~122 (2024)
3. Haran, V., "Deciphering the epitranscriptomic signatures in cell fate determination and development", Stem Cell Rev. Rep, 15, pp.474~496 (2019)
4. Kim, Y.-K., "RNA therapy: rich history, various applications and unlimited future prospects", Exp. Mol. Med, 54, pp.455~465 (2022)
5. Peng, H., "N(6)-methyladenosine(m(6)A)in 18S rRNA promotes fatty acid metabolism and oncogenic transformation", Nat. Metab, 4, pp.1041~1054 (2022)
6. Martinez, N. M., "Pseudouridine synthases modify human pre-mRNA co transcriptionally and affect pre-mRNA processing", Mol. Cell, 82, pp.645~659 (2022)
7. Jack, K., "rRNA pseudouridylation defects affect ribosomal ligand binding and translational fidelity from yeast to human cells", Mol. Cell, 44, pp.660~666 (2011)
8. Panousis, N. I., "Combined genetic and transcriptome analysis of patients with SLE : distinct, targetable signatures for susceptibility and severity", Ann. Rheum. Dis, 78, pp.1079~1089 (2019)
9. Adwan, L., "Epigenetics : a novel therapeutic approach for the treatment of Alzheimer’s disease", Pharm. Ther, 139, pp.41~50 (2013)
10. Ge, X., "Role of LncRNAs in the Epithelial Mesenchymal Transition in Hepatocellular Carcinoma", Front Oncol, 11, pp.690800~ (2021)
11. Orsolic, I., "Genetic and epigenetic defects of the RNA modification machinery in cancer", Trends Genet, 39, pp.74~88 (2023)
12. Xue, C., "Role of main RNA modifications in cancer : N6-methyladenosine, 5methylcytosine, and pseudouridine", Signal Transduct. Target. Ther, 7, pp.142~ (2022)
13. Wei, L., "Noncoding RNAs in gastric cancer : implications for drug resistance", Mol. Cancer, 19, pp.62~ (2020)
14. Sciarrillo, R., "The role of alternative splicing in cancer : from oncogenesis to drug resistance", Drug Resist Updat, 53, pp.100728~ (2020)
15. Cox, A., "Strategies to deliver RNA by nanoparticles for therapeutic potential", Mol. Asp. Med, 83, pp.100991~ (2022)
16. Toden, S., "Non-coding RNAs and potential therapeutic targeting in cancer", Biochim Biophys. Acta Rev. Cancer, 1875, pp.188491~ (2021)
17. Booth, B. J., "RNA editing : Expanding the potential of RNA therapeutics", Mol. Ther, 31, pp.1533~1549 (2023)
18. Adams, D., "Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis", N. Engl. J. Med, 379, pp.11~21 (2018)
19. Yuan, T. L., "Development of siRNA payloads to target KRAS-mutant cancer", Cancer Discov, 4, pp.1182~1197 (2014)
20. Schultheis, B., "First-in-human phase I study of the liposomal RNA inter ference therapeutic Atu027 in patients with advanced solid tumors", J. Clin. Oncol, 32, pp.4141~4148 (2014)
21. Hattab, D., "Clinical advances of siRNA-based nanotherapeutics for cancer treatment", Pharmaceutics, 13, pp.1009~ (2021)
22. Di Giammartino, D. C., "Mechanisms and consequences of alternative polyadenylation", Mol. Cell, 43, pp.853~866 (2011)
23. Yuan, F., "Alternative polyadenylation of mRNA and its role in cancer", Genes Dis, 8, pp.61~72 (2021)
24. Elkon, R., "Alternative cleavage and polyadenylation:extent, regulation and function", Nat. Rev. Genet, 14, pp.496~506 (2013)
25. Lee, S. H., "Widespread intronic polyadenylation inactivates tumour sup pressor genes in leukaemia", Nature, 561, pp.127~131 (2018)
26. Tan, S., "CPSF6 links alternative polyadenylation to metabolism adaption in hepatocellular carcinoma progression", J. Exp. Clin. Cancer Res, 40, pp.85~ (2021)
27. Berkovits, B. D., "Alternative 3′ UTRs act as scaffolds to regulate membrane protein localization", Nature, 522, pp.363~367 (2015)
28. Gruber, A. J., "Alternative cleavage and polyadenylation in health and disease", Nat. Rev. Genet, 20, pp.599~614 (2019)
29. Wiestner, A., "Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased pro liferation rate and shorter survival", Blood, 109, pp.4599~4606 (2007)
30. Tian, B., "Alternative polyadenylation of mRNA precursors", Nat. Rev. Mol. Cell Biol, 18, pp.18~30 (2017)
31. Erson-Bensan, A. E., "Alternative polyadenylation: another Foe in cancer", Mol. Cancer Res, 14, pp.507~517 (2016)
32. Masamha, C. P., "CFIm25 links alternative polyadenylation to glioblastoma tumour suppression", Nature, 510, pp.412~416 (2014)
33. Wang, E. T., "Alternative isoform regulation in human tissue transcriptomes", Nature, 456, pp.470~476 (2008)
34. Ule, J., "Alternative splicing regulatory networks : functions, mechanisms, and evolution", Mol. Cell, 76, pp.329~345 (2019)
35. Bonnal, S. C., "Roles and mechanisms of alternative splicing in cancer — implications for care", Nat. Rev. Clin. Oncol, 17, pp.457~474 (2020)
36. Kahles, A., "Comprehensive analysis of alternative splicing across tumors from 8,705 patients", Cancer Cell, 34, pp.211~224 (2018)
37. Dou, Z., "Aberrant Bcl-x splicing in cancer : from molecular mechanism to therapeutic modulation", J. Exp. Clin. Cancer Res, 40, pp.194~ (2021)
38. Wahl, M. C., "The spliceosome: design principles of a dynamic RNP machine", Cell, 136, pp.701~718 (2009)
39. Bradley, R. K., "RNA splicing dysregulation and the hallmarks of cancer", Nat. Rev. Cancer, 23, pp.135~155 (2023)
40. Howard, J. M., "The RNAissance family : SR proteins as multifaceted regulators of gene expression", Wiley Interdiscip. Rev. RNA, 6, pp.93~110 (2015)
41. Giudice, J., "Splicing regulation through biomolecular condensates and membraneless organelles", Nat. Rev. Mol. Cell Biol (2024)
42. Nishikura, K., "A-to-I editing of coding and non-coding RNAs by ADARs", Nat. Rev. Mol. Cell Biol, 17, pp.83~96 (2016)
43. Eisenberg, E., "A-to-I RNA editing — immune protector and transcriptome diversifier", Nat. Rev. Genet, 19, pp.473~490 (2018)
44. Liu, J., "ADAR1-mediated RNA editing and its role in cancer", Front Cell Dev. Biol, 10, pp.956649~ (2022)
45. Yuan, J., "Biological roles of A-to-I editing : implications in innate immunity, cell death, and cancer immunotherapy", J. Exp. Clin. Cancer Res, 42, pp.149~ (2023)
46. Chen, L., "Recoding RNA editing of AZIN1 predisposes to hepatocellular carcinoma", Nat. Med, 19, pp.209~216 (2013)
47. Fritzell, K., "ADARs and editing: the role of A to-I RNA modification in cancer progression", Semin Cell Dev. Biol, 79, pp.123~130 (2018)
48. Pecori, R., "Functions and consequences of AID", APOBEC-mediated DNA and RNA deamination, 2022, pp.23, 505~518
49. Smith, H. C., "RNA binding to APOBEC deaminases; not simply a substrate for C to U editing", RNA Biol, 14, pp.1153~1165 (2017)
50. Blanc, V., "Apobec1 complementation factor overexpression promotes hepatic steatosis, fibrosis, and hepatocellular cancer", J. Clin. Invest, 131, pp.e138699~ (2021)
51. Vanharanta, S., "Loss of the multifunctional RNA-binding protein RBM47 as a source of selectable metastatic traits in breast cancer", Elife, 3, pp.e02734~ (2014)
52. Boo, S. H., "The emerging role of RNA modifications in the regulation of mRNA stability", Exp. Mol. Med, 52, pp.400~408 (2020)
53. Jiang, X., "The role of m6A modification in the biological functions and diseases", Signal Transduct. Target. Ther, 6, pp.74~ (2021)
54. Zaccara, S., "Reading, writing and erasing mRNA methylation", Nat. Rev. Mol. Cell Biol, 20, pp.608~624 (2019)
55. Barbieri, I., "Role of RNA modifications in cancer", Nat. Rev. Cancer, 20, pp.303~322 (2020)
56. Cao, Y., "Regulation of SUMOylation on RNA meta bolism in cancers", Front Mol. Biosci, 10, pp.1137215~ (2023)
57. Cowling, V. H., "Enhanced mRNA cap methylation increases Cyclin D1 expression and promotes cell transformation", Oncogene, 29, pp.930~936 (2010)
58. Arango, D., "Acetylation of cytidine in mRNA promotes translation efficiency", Cell, 175, pp.1872~1886 (2018)
59. Luo, J., "Emerging role of RNA acetylation modification ac4C in diseases : Current advances and future challenges", Biochem. Pharm, 213, pp.115628~ (2023)
60. Arango, D., "Direct epitranscriptomic regulation of mammalian translation initiation through N4-acetylcytidine", Mol. Cell, 82, pp.2797~2814 (2022)
61. Jin, C., "Acetyltransferase NAT10 regulates the Wnt", β-catenin signaling pathway to promote colorectal cancer progression via ac4C acetylation of KIF23mRNA, 2022, pp.41, 345~
62. Deng, M., "Helicobacter pylori-induced NAT10 stabilizes MDM2 mRNA via RNA acetylation to facilitate gastric cancer progression", J. Exp. Clin. Cancer Res, 42, pp.9~ (2023)
63. Zheng, X., "N-acetyltransferase 10 promotes colon cancer progression by inhibiting ferroptosis through N4-acetylation and stabilization of ferroptosis suppressor protein 1 (FSP1) mRNA", Cancer Commun. (Lond.), 42, pp.1347~1366 (2022)
64. Xing, J., "LncRNA-encoded peptide : functions and predicting methods", Front Oncol, 10, pp.622294~ (2020)
65. Pang, Y., "Peptide SMIM30 promotes HCC development by inducing SRC", YES1 membrane anchoring and MAPK pathway activation, 2020, pp.73, 1155~1169
66. Wang, Y., "LncRNA-encoded polypeptide ASRPS inhibits triple-negative breast cancer angiogenesis", J. Exp. Med, 217, pp.jem.20190950~ (2020)
67. Xiang, X., "Cellular senescence in hepatocellular carcinoma induced by a long non-coding RNA-encoded peptide PINT87aa by blocking FOXM1-mediated PHB2", Theranostics, 11, pp.4929~4944 (2021)
68. Wang, Y., "tRNA modifications : insights into their role in human cancers", Trends Cell Biol, 33, pp.1035~1048 (2023)
69. Guzzi, N., "Pseudouridylation of tRNA-derived fragments steers translational control in stem cells", Cell, 173, pp.1204~1216 (2018)
70. Marshall, L., "Non-coding RNA production by RNA polymerase III is implicated in cancer", Nat. Rev. Cancer, 8, pp.911~914 (2008)
71. Xiong, Q., "Small RNA modifications : regulatory molecules and potential applications", J. Hematol. Oncol, 16, pp.64~ (2023)
72. Zhou, S., "The Pol III transcriptome : basic features, recurrent patterns, and emerging roles in cancer", Wiley Interdiscip. Rev. RNA, 14, pp.e1782~ (2023)
73. Lam, J. K., "siRNA Versus miRNA as Ther apeutics for Gene Silencing", Mol. Ther. Nucleic Acids, 4, pp.e252~ (2015)
74. Rupaimoole, R., "MicroRNA therapeutics : towards a new era for the management of cancer and other diseases", Nat. Rev. Drug Discov, 16, pp.203~222 (2017)
75. Flynn, R. A., "Small RNAs are modified with N-glycans and displayed on the surface of living cells", Cell, 184, pp.3109~3124 (2021)
76. Zheng, L., "The glycosylation of immune checkpoints and their applications in oncology", Pharm. (Basel), 15, pp.1451~ (2022)
77. Tang, Q., "RNA modifications in cancer", Br. J. Cancer, 129, pp.204~221 (2023)
78. Cui, W., "tRNA modifications and modifying enzymes in disease, the potential therapeutic targets", Int J. Biol. Sci, 19, pp.1146~1162 (2023)
79. Oerum, S., "A comprehensive review of m6A", m6Am RNA methyltransferase structures, 2021, pp.49, 7239~7255
80. Liu, Y., "tRNA-m1A modification promotes T cell expansion via efficient MYC protein synthesis", Nat. Immunol, 23, pp.1433~1444 (2022)
81. Delaunay, S., "Mitochondrial RNA modifications shape metabolic plasticity in metastasis", Nature, 607, pp.593~603 (2022)
82. Cui, Q., "Targeting PUS7 suppresses tRNA pseudouridylation and glio blastoma tumorigenesis", Nat. Cancer, 2, pp.932~949 (2021)
83. Zhang, L., "Classification, function, and advances in tsRNA in non neoplastic diseases", Cell Death Dis, 14, pp.748~ (2023)
84. Fu, M., "Emerging roles of tRNA-derived fragments in cancer", Mol. Cancer, 22, pp.30~ (2023)
85. Lee, S., "Emerging roles of tRNA-derived small RNAs in cancer biology", Exp. Mol. Med, 55, pp.1293~1304 (2023)
86. Bartel, D. P., "MicroRNAs : target recognition and regulatory functions", Cell, 136, pp.215~233 (2009)
87. Xu, X., "A-to-I-edited miRNA-379-5p inhibits cancer cell proliferation through CD97-induced apoptosis", J. Clin. Invest, 129, pp.5343~5356 (2019)
88. Kim, H. S., "ADAR1-dependent miR-3144-3p editing simultaneously induces MSI2 expression and suppresses SLC38A4 expression in liver cancer", Exp. Mol. Med, 55, pp.95~107 (2023)
89. Konno, M., "Distinct methylation levels of mature microRNAs in gastro intestinal cancers", Nat. Commun, 10, pp.3888~ (2019)
90. Chen, Y., "Interaction between N6methyladenosine(m6A)modification and noncoding RNAs in cancer", Mol. Cancer, 19, pp.94~ (2020)
91. Lee, Y., "Molecular mechanisms driving mRNA degradation by m(6)A modification", Trends Genet, 36, pp.177~188 (2020)
92. Cheray, M., "Cytosine methylation of mature microRNAs inhibits their functions and is associated with poor prognosis in glioblastoma multiforme", Mol. Cancer, 19, pp.36~ (2020)
93. Pandolfini, L., "METTL1 promotes let-7 MicroRNA processing via m7G methylation", Mol. Cell, 74, pp.1278~1290 (2019)
94. Kurimoto, R., "The tRNA pseudouridine synthase TruB1 regulates the maturation of let-7 miRNA", Embo j, 39, pp.e104708~ (2020)
95. Tomasello, L., "The MicroRNA family gets wider : the IsomiRs classification and role", Front Cell Dev. Biol, 9, pp.668648~ (2021)
96. Lausten, M. A., "A Review of IsomiRs in colorectal cancer", Non coding RNA, 9, pp.34~ (2023)
97. Telonis, A. G., "Knowledge about the presence or absence of miRNA iso forms(isomiRs)can successfully discriminate amongst 32 TCGA cancer types", Nucleic Acids Res, 45, pp.2973~2985 (2017)
98. Zelli, V., "Emerging role of isomiRs in cancer: state of the art and recent advances", Genes (Basel), 12, pp.1447~ (2021)
99. Park, S., "hnRNPC induces isoform shifts in miR-21-5p leading to cancer development", Exp. Mol. Med, 54, pp.812~824 (2022)
100. Telonis, A. G., "Beyond the one-locus one-miRNA paradigm: microRNA isoforms enable deeper insights into breast cancer heterogeneity", Nucleic Acids Res, 43, pp.9158~9175 (2015)
101. Ni, H., "Higher variety and quantity of microRNA-139-5p isoforms confer suppressive role in hepatocellular carcinoma", J. Cell Biochem, 119, pp.6806~6813 (2018)
102. Mjelle, R., "Small RNA expression from viruses, bacteria and human miRNAs in colon cancer tissue and its association with microsatellite instability and tumor location", BMC Cancer, 19, pp.161~ (2019)
103. Mamontova, V., "Commuting to work : nucleolar long non-coding RNA control ribosome biogenesis from near and far", Non coding RNA, 7, pp.42~ (2021)
104. Murphy, M. R., "Long non-coding RNA generated from CDKN1A gene by alternative polyadenylation regulates p21 expression during DNA damage response", Nucleic Acids Res, 51, pp.11911~11926 (2023)
105. Wang, R., "A compendium of conserved cleavage and polyadenylation events in mammalian genes", Genome Res, 28, pp.1427~1441 (2018)
106. Ransohoff, J. D., "The functions and unique features of long intergenic non-coding RNA", Nat. Rev. Mol. Cell Biol, 19, pp.143~157 (2018)
107. Guo, C. J., "Distinct processing of lncRNAs contributes to non-conserved functions in stem cells", Cell, 181, pp.621~636 (2020)
108. Huarte, M., "The emerging role of lncRNAs in cancer", Nat. Med, 21, pp.1253~1261 (2015)
109. Schmitt, A. M., "Long noncoding RNAs in cancer pathways", Cancer Cell, 29, pp.452~463 (2016)
110. Yu, X. M., "N4-acetylcytidine modification of lncRNA CTC-490G23.2 pro motes cancer metastasis through interacting with PTBP1 to increase CD44alternative splicing", Oncogene, 42, pp.1101~1116 (2023)
111. Chandra Gupta, S., "Potential of long non-coding RNAs in cancer patients : From biomarkers to therapeutic targets", Int J. Cancer, 140, pp.1955~1967 (2017)
112. Khan, M. R., "Distinct regulatory functions and biological roles of lncRNA splice variants", Mol. Ther. Nucleic Acids, 32, pp.127~143 (2023)
113. Li, Y., "A Wnt-induced lncRNA-DGCR5 splicing switch drives tumor promoting inflammation in esophageal squamous cell carcinoma", Cell Rep, 42, pp.112542~ (2023)
114. Liu, M., "The interplay between non-coding RNAs and alternative splicing : from regulatory mechanism to therapeutic implications in cancer", Theranostics, 13, pp.2616~2631 (2023)
115. Silvestris, D. A., "De Novo A-to-I RNA editing discovery in lncRNA", Cancers (Basel), 12, pp.2959~ (2020)
116. Deng, S. J., "Nutrient stress-dysregulated antisense lncRNA GLS-AS impairs GLS-mediated metabolism and represses pancreatic cancer progression", Cancer Res, 79, pp.1398~1412 (2019)
117. Stellos, K., "Adenosine-to-inosine RNA editing controls cathepsin S expres sion in atherosclerosis by enabling HuR-mediated post-transcriptional regula tion", Nat. Med, 22, pp.1140~1150 (2016)
118. Bussemakers, M. J., "DD3 : a new prostate-specific gene, highly over expressed in prostate cancer", Cancer Res, 59, pp.5975~5979 (1999)
119. Salameh, A., "PRUNE2 is a human prostate cancer suppressor regulated by the intronic long noncoding RNA PCA3", Proc. Natl Acad. Sci. USA, 112, pp.8403~8408 (2015)
120. Liao, Y., "A-to-I RNA editing as a tuner of noncoding RNAs in cancer", Cancer Lett, 494, pp.88~93 (2020)
121. He, Y., "Novel insight into the functions of N(6)‑methyladenosine modified lncRNAs in cancers(Review)", Int J. Oncol, 61, pp.152~ (2022)
122. Meng, Q., "Crosstalk between m6A and coding", non-coding RNA in cancer and detection methods of m6A modification resi dues, 2023, pp.15, 6577~6619
123. Wang, Z. W., "SRSF3-mediated regulation of N6-methyladenosine mod ification-related lncRNA ANRIL splicing promotes resistance of pancreatic cancer to gemcitabine", Cell Rep, 39, pp.110813~ (2022)
124. Patil, D. P., "m6A RNA methylation promotes XIST-mediated transcriptional repression", Nature, 537, pp.369~373 (2016)
125. Chen, L., "METTL3-mediated m6A modification stabilizes TERRA and main tains telomere stability", Nucleic Acids Res, 50, pp.11619~11634 (2022)
126. Shaath, H., "Long non-coding RNA and RNA-binding protein interactions in cancer : Experimental and machine learning approaches", Semin. Cancer Biol, 86, pp.325~345 (2022)
127. Zuo, X., "M6A-mediated upregulation of LINC00958 increases lipogenesis and acts as a nanotherapeutic target in hepatocellular carcinoma", J. Hematol. Oncol, 13, pp.5~ (2020)
128. Sun, Z., "Aberrant NSUN2-mediated m(5)C modification of H19 lncRNA is associated with poor differentiation of hepatocellular carcinoma", Oncogene, 39, pp.6906~6919 (2020)
129. Peng, Y. L., "Identification and validation of a m7G-related lncRNA signature for predicting the prognosis and therapy response in hepatocellular carcinoma", PLoS ONE, 18, pp.e0289552~ (2023)
130. Cerneckis, J., "Decoding pseudouridine : an emerging target for therapeutic development", Trends Pharm. Sci, 43, pp.522~535 (2022)
131. Carlile, T. M., "Pseudouridine profiling reveals regulated mRNA pseudour idylation in yeast and human cells", Nature, 515, pp.143~146 (2014)
132. Jacob, R., "The Dark Side of the Epitranscriptome : Chemical Modifications in Long Non-Coding RNAs", Int J. Mol. Sci, 18, pp.2387~ (2017)
133. Liu, S. Y., "LncRNA PCAT1 interacts with DKC1 to regulate proliferation, invasion and apoptosis in NSCLC cells via the VEGF", AKT, Caspase9 pathway, pp.Cell Transpl, 2021[DOI]
134. Zhang, L., "The role of N6-methyladenosine(m6A)modification in the regulation of circRNAs", Mol. Cancer, 19, pp.105~ (2020)
135. Yang, Q., "Circular RNAs : expression, localization, and therapeutic potentials", Mol. Ther, 29, pp.1683~1702 (2021)
136. Roy, S., "Diagnostic efficacy of circular RNAs as noninvasive, liquid biopsy biomarkers for early detection of gastric cancer", Mol. Cancer, 21, pp.42~ (2022)
137. Gu, X., "Vital roles of m(5)C RNA modification in cancer and immune cell biology", Front Immunol, 14, pp.1207371~ (2023)
138. Zhu, L. R., "Advances in RNA epigenetic modifications in hepatocellular carcinoma and potential targeted intervention strategies", Front Cell Dev. Biol, 9, pp.777007~ (2021)
139. Salmena, L., "A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language?", Cell, 146, pp.353~358 (2011)
140. Zheng, Z. -Q., "Long noncoding RNA FAM225A promotes nasopharyngeal carcinoma tumorigenesis and metastasis by acting as ceRNA to sponge miR 590-3p", miR-1275 and upregulate ITGB3, 2019, pp.79, 4612~4626
141. Park, H. J., "3′ UTR shortening represses tumor-suppressor genes in trans by disrupting ceRNA crosstalk", Nat. Genet, 50, pp.783~789 (2018)
142. Liu, B., "The regulatory role of antisense lncRNAs in cancer", Cancer Cell Int, 21, pp.459~ (2021)
143. Gong, C., "lncRNAs transactivate STAU1-mediated mRNA decay by duplexing with 3’ UTRs via Alu elements", Nature, 470, pp.284~288 (2011)
144. Su, T., "Super enhancer-regulated LncRNA LINC01089 induces alternative splicing of DIAPH3 to drive hepatocellular carcinoma metastasis", Cancer Res, 83, pp.4080~4094 (2023)
145. Jawad, S. F., "The strict regulation of HIF-1α by non-coding RNAs : new insight towards proliferation, metastasis, and therapeutic resistance strategies", Cancer Metastasis Rev, 43, pp.5~27 (2024)
146. Shen, P., "Correction : CircNEIL3 regulatory loop promotes pancreatic ductal adenocarcinoma progression via miRNA sponging and A-to-IRNA-editing", Mol. Cancer, 21, pp.165~ (2022)
147. Araki, S., "Targeting pre-mRNA splicing in cancers : roles, inhibitors, and therapeutic opportunities", Front Oncol, 13, pp.1152087~ (2023)
148. Eskens, F. A., "Phase I pharmacokinetic and pharmacodynamic study of the f irst-in-class spliceosome inhibitor E7107 in patients with advanced solid tumors", Clin. Cancer Res, 19, pp.6296~6304 (2013)
149. Seiler, M., "H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers", Nat. Med, 24, pp.497~504 (2018)
150. Bowling, E. A., "Spliceosome-targeted therapies trigger an antiviral immune response in triple-negative breast cancer", Cell, 184, pp.384~403 (2021)
151. Lu, S. X., "Pharmacologic modulation of RNA splicing enhances anti-tumor immunity", Cell, 184, pp.4032~4047 (2021)
152. Yankova, E., "Small-molecule inhibition of METTL3 as a strategy against myeloid leukaemia", Nature, 593, pp.597~601 (2021)
153. Zhang, L., "MicroRNA-34 family : a potential tumor suppressor and therapeutic candidate in cancer", J. Exp. Clin. Cancer Res, 38, pp.53~ (2019)
154. Hong, D. S., "Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours", Br. J. Cancer, 122, pp.1630~1637 (2020)
155. Reid, G., "Clinical development of TargomiRs, a miRNA mimic-based treatment for patients with recurrent thoracic cancer", Epigenomics, 8, pp.1079~1085 (2016)
156. Wang, X., "MicroRNA-16 functions as a tumor-suppressor gene in oral squamous cell carcinoma by targeting AKT3 and BCL2L2", J. Cell Physiol, 233, pp.9447~9457 (2018)
157. Hu, Y., "miR-22 gene therapy treats HCC by promoting anti-tumor immunity and enhancing metabolism", Mol. Ther, 31, pp.1829~1845 (2023)
158. Tay, D. J. T., "Targeting RNA editing of antizyme inhibitor 1 : A potential oligonucleotide-based antisense therapy for cancer", Mol. Ther, 29, pp.3258~3273 (2021)
159. Marcucci, G., "Phase 1 and pharmacodynamic studies of G3139, a Bcl-2antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia", Blood, 101, pp.425~432 (2003)
160. Marshall, J. L., "A phase II trial of ISIS 3521 in patients with metastatic colorectal cancer", Clin. Colorectal Cancer, 4, pp.268~274 (2004)
161. Bogdahn, U., "Targeted therapy for high-grade glioma with the TGF-β2inhibitor trabedersen : results of a randomized and controlled phase IIb study", Neuro Oncol, 13, pp.132~142 (2011)
162. Wahlestedt, C., "Targeting long non-coding RNA to therapeutically upregulate gene expression", Nat. Rev. Drug Discov, 12, pp.433~446 (2013)
163. Khorkova, O., "Long non-coding RNA-targeting therapeutics : discovery and development update", Expert Opin. Drug Discov, 18, pp.1011~1029 (2023)
164. Arun, G., "Differentiation of mammary tumors and reduction in metastasis upon Malat1 lncRNA loss", Genes Dev, 30, pp.34~51 (2016)
165. Li, M., "Antisense oligonucleotides targeting lncRNA AC104041.1 induces antitumor activity through Wnt2B", β-catenin pathway in head and neck squa mous cell carcinomas, 2020, pp.11, 672~
166. Song, W., "TRERNA1 upregulation mediated by HBx promotes sorafenib resistance and cell proliferation in HCC via targeting NRAS by sponging miR-223p", Mol. Ther, 29, pp.2601~2616 (2021)
167. Tang, S., "An artificial lncRNA targeting multiple miRNAs overcomes sor afenib resistance in hepatocellular carcinoma cells", Oncotarget, 7, pp.73257~73269 (2016)
168. Amicone, L., "The lncRNA HOTAIR : a pleiotropic reg ulator of epithelial cell plasticity", J. Exp. Clin. Cancer Res, 42, pp.147~ (2023)
169. Bauman, J. A., "Anti-tumor activity of splice switching oligonucleotides", Nucleic Acids Res, 38, pp.8348~8356 (2010)
170. Dewaele, M., "Antisense oligonucleotide-mediated MDM4 exon 6 skipping impairs tumor growth", J. Clin. Invest, 126, pp.68~84 (2016)
171. Havens, M. A., "Splice-switching antisense oligonucleotides as therapeutic drugs", Nucleic Acids Res, 44, pp.6549~6563 (2016)
172. Nielsen, T. O., "Directing HER4 mRNA expression towards the CYT2 isoform by antisense oli gonucleotide decreases growth of breast cancer cells in vitro and in vivo", Br. J. Cancer, 108, pp.2291~2298 (2013)
173. Zammarchi, F., "Antitumorigenic potential of STAT3 alternative splicing modulation", Proc. Natl Acad. Sci. USA, 108, pp.17779~17784 (2011)
174. Godfrey, C., "Delivery is key : lessons learnt from developing splice-switching antisense therapies", EMBO Mol. Med, 9, pp.545~557 (2017)
175. Comiskey, D. F. Jr., "SRSF2regulation of MDM2 reveals splicing as a therapeutic vulnerability of the p53pathway", Mol. Cancer Res, 18, pp.194~203 (2020)
176. Wang, Z., "Manipulation of PK-M mutually exclusive alternative splicing by antisense oligonucleotides", Open Biol, 2, pp.120133~ (2012)

관련 논문AI추천